MedTrace Logo

Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia (MCMP)

NCT02303587 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 424

Last updated 2021-01-08

No results posted yet for this study

Summary

The study is designed to investigate difference in percentage of presentation of atelectasis, bronchiectasis, bronchiolitis obliterans, or consolidation in 6 months after discharge in those treated with a low dose regimen of methylprednisolone initiated with 2 or 4 mg/kg/d for 3 days followed by tapering, combined with sequential treatment with azithromycin versus a high dose regimen of methylprednisolone initiated with 10 mg/kg/d for 3 days followed by tapering, combined with sequential treatment with azithromycin.

Conditions

  • Mycoplasma Pneumoniae Pneumonia

Interventions

DRUG

methylprednisolone

Sponsors & Collaborators

  • Shengjing Hospital

    collaborator OTHER

  • Children's Hospital of The Capital Institute of Pediatrics

    collaborator OTHER

  • Shanxi Provincial Maternity and Children's Hospital

    collaborator OTHER

  • Baoding Children's Hospital

    collaborator OTHER

  • Beijing Children's Hospital

    lead OTHER

Principal Investigators

  • Kunling Shen, MD,PhD · Beijing Children's Hospital of Capital Medical University, China

  • Baoping Xu, MD, PhD · Beijing Children's Hospital of Capital Medical University, China

  • Xiaoxia Peng, MD, PhD · Beijing Children's Hospital of Capital Medical University, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
29 Days
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2019-10-16
Completion
2019-10-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303587 on ClinicalTrials.gov